Regen BioPharma (RGBPP) EBIAT (2016 - 2025)
Regen BioPharma (RGBPP) has disclosed EBIAT for 13 consecutive years, with -$572471.0 as the latest value for Q3 2025.
- On a quarterly basis, EBIAT fell 768.67% to -$572471.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.3 million, a 90.73% decrease, with the full-year FY2025 number at -$1.3 million, down 90.72% from a year prior.
- EBIAT was -$572471.0 for Q3 2025 at Regen BioPharma, down from -$167292.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of $67.0 million in Q2 2022 to a low of -$67.1 million in Q1 2022.
- A 5-year average of -$356542.0 and a median of -$122454.0 in 2024 define the central range for EBIAT.
- Biggest YoY gain for EBIAT was 994.07% in 2022; the steepest drop was 15270.58% in 2022.
- Regen BioPharma's EBIAT stood at $2.6 million in 2021, then plummeted by 38.16% to $1.6 million in 2022, then plummeted by 121.38% to -$349760.0 in 2023, then plummeted by 47.35% to -$515384.0 in 2024, then fell by 11.08% to -$572471.0 in 2025.
- Per Business Quant, the three most recent readings for RGBPP's EBIAT are -$572471.0 (Q3 2025), -$167292.0 (Q2 2025), and -$19354.0 (Q1 2025).